Indian Pharma CDMOs Remain Resilient Amid Proposed US Tariffs of Up to 25 Percent

The Indian pharmaceutical sector, particularly Contract Development and Manufacturing Organizations (CDMOs), is poised to withstand the impact of proposed 10-25% tariffs from the United States, according to a recent report by B&K Securities. With annual exports to the U.S. estimated between $9 billion and $10 billion, industry insiders believe that any potential cost increases can largely be transferred to end customers, thereby minimizing financial strain.

Despite growing concerns regarding new trade restrictions, the report indicates that Indian pharma service providers expect only marginal effects on their U.S. business operations. The U.S. remains a crucial market for Indian CDMOs, which supply 40-45% of the total generic drug volume in the country. This significant market share positions them well to absorb any tariff-related challenges.

The proposed tariffs could affect a range of products, particularly non-strategic items such as everyday consumer goods. However, experts assert that export formulation companies can effectively pass on any price impacts to customers. This ability to adjust pricing is critical in maintaining competitive advantages in a market where Indian firms play a vital role in supplying key starting materials (KSMs), active pharmaceutical ingredients (APIs), and finished formulations.

Moreover, the trend of global pharmaceutical companies diversifying their supply chains to include Indian CDMOs as part of a China+1 strategy continues to gain traction. Favorable exchange rates and an increase in requests for quotations (RFQs) are further driving growth in the sector.

Indian CDMOs are not resting on their laurels; they are actively investing in expanding capabilities, particularly in specialized areas like Antibody-Drug Conjugates (ADCs), peptides, and Cell and Gene Therapy (CGT). These advancements position Indian companies to capitalize on emerging opportunities in the expansive $180 billion global CDMO market.

Despite uncertainties surrounding U.S. trade policies, Indian pharmaceutical manufacturers are expected to enhance their global presence through continuous innovation and technological advancements. As they adapt to shifting market dynamics, the resilience of the Indian CDMO sector is likely to play a pivotal role in the broader pharmaceutical landscape.